Abstract
It has been demonstrated that 5-HT1A receptors play an important role in the pathophysiology of schizophrenia. Because Gastrodia elata Bl (GE) modulates the serotonergic system, we examined whether GE could affect phencyclidine (PCP)-induced abnormal behavior in mice. Repeated treatment with PCP increased immobility time, while it decreased social interaction time and recognition memory. PCP-induced abnormal behaviors were significantly attenuated by GE, and these effects were comparable to those of 8-OH-DPAT, a 5-HT1A receptor agonist. Furthermore, GE-mediated effects were counteracted by WAY 100635, a 5-HT1A receptor antagonist. Our results suggest that the antipsychotic effects of GE are, at least in part, mediated via activation of 5-HT1A in mice.
Keywords: Gastrodia elata Bl, phencyclidine, schizophrenia, 5-HT1A receptors, chronic, devastating, anxiolytic, anti-depressant, anti-convulsant, anti-oxidant, anti-depressant effects
Current Neuropharmacology
Title: Effects of Gastrodia Elata Bl on Phencyclidine-Induced Schizophrenia-Like Psychosis in Mice
Volume: 9 Issue: 1
Author(s): E.-J. Shin, J.-M. Kim, X.-K. T. Nguyen, T.-T. L. Nguyen, S. Y. Lee, J.-H. Jung, M. J. Kim, W. K. Whang, K. Yamada, T. Nabeshima and H.-C. Kim
Affiliation:
Keywords: Gastrodia elata Bl, phencyclidine, schizophrenia, 5-HT1A receptors, chronic, devastating, anxiolytic, anti-depressant, anti-convulsant, anti-oxidant, anti-depressant effects
Abstract: It has been demonstrated that 5-HT1A receptors play an important role in the pathophysiology of schizophrenia. Because Gastrodia elata Bl (GE) modulates the serotonergic system, we examined whether GE could affect phencyclidine (PCP)-induced abnormal behavior in mice. Repeated treatment with PCP increased immobility time, while it decreased social interaction time and recognition memory. PCP-induced abnormal behaviors were significantly attenuated by GE, and these effects were comparable to those of 8-OH-DPAT, a 5-HT1A receptor agonist. Furthermore, GE-mediated effects were counteracted by WAY 100635, a 5-HT1A receptor antagonist. Our results suggest that the antipsychotic effects of GE are, at least in part, mediated via activation of 5-HT1A in mice.
Export Options
About this article
Cite this article as:
Shin E.-J., Kim J.-M., T. Nguyen X.-K., L. Nguyen T.-T., Y. Lee S., Jung J.-H., J. Kim M., K. Whang W., Yamada K., Nabeshima T. and Kim H.-C., Effects of Gastrodia Elata Bl on Phencyclidine-Induced Schizophrenia-Like Psychosis in Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017263
DOI https://dx.doi.org/10.2174/157015911795017263 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Approach to Combat COVID-19 Infection: Emerging
Tools for Accelerating Drug Research
Current Drug Discovery Technologies Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases
Current Topics in Medicinal Chemistry Seizures Secondary to Bupropion Misuse/Abuse: Three Cases
Adolescent Psychiatry A Salicylic Acid-Based Analogue Discovered from Virtual Screening as a Potent Inhibitor of Human 20α-Hydroxysteroid Dehydrogenase
Medicinal Chemistry Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review
Current Clinical Pharmacology Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Rubosixtaurin and other pkc Inhibitors in Diabetic Retinopathy and Macular Edema. Review
Current Diabetes Reviews Existing and Emerging Therapies for Acute Gout and Long-Term Urate Lowering
Current Rheumatology Reviews Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews Development, Pre-clinical Investigation and Histopathological Evaluation of Metronidazole Loaded Topical Formulation for Treatment of Skin Inflammatory Disorders
Drug Delivery Letters Novel Approaches to the Pharmacotherapy of Obesity
Current Pharmaceutical Design Dissecting the Biological Effects of Isoflurane through the Mechanistic Target of Rapamycin (mTOR) and microRNAs (miRNAs)
Current Neurovascular Research Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets The Follow-Up of Dietary Treatment of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Drugs in Pediatric Ischemic Stroke
Current Drug Targets GABA-A Receptors as Molecular Sites of Ethanol Action. Direct or Indirect Actions?
Current Topics in Medicinal Chemistry Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry